Pages that link to "Item:Q4376005"
From MaRDI portal
The following pages link to Group-Sequential Analysis Incorporating Covariate Information (Q4376005):
Displaying 26 items.
- Sample size determination for group sequential test under fractional Brownian motion (Q358885) (← links)
- Use of a side effect as a covariate in a problem of sequential analysis (Q1200660) (← links)
- Control of type I error rates in Bayesian sequential designs (Q1738139) (← links)
- Sequential tests of multiple hypotheses controlling type I and II familywise error rates (Q2250703) (← links)
- Multi-center clinical trials: randomization and ancillary statistics (Q2271337) (← links)
- Sequential sampling in prospective observational studies (Q2686025) (← links)
- A rejection principle for sequential tests of multiple hypotheses controlling familywise error rates (Q2791825) (← links)
- Sequential Analysis of Censored Data with Linear Transformation Models (Q2888570) (← links)
- Sequential Analysis of Longitudinal Data in a Prospective Nested Case-Control Study (Q3076031) (← links)
- Discrimination analysis when the variates are grouped and observed in sequential order (Q3474035) (← links)
- GROUP SEQUENTIAL TESTS WITH OUTCOME-DEPENDENT TREATMENT ASSIGNMENT (Q4331107) (← links)
- An Adaptive Approach to Implementing Bivariate Group Sequential Clinical Trial Designs (Q4430338) (← links)
- Design and monitoring of multi‐arm multi‐stage clinical trials (Q4556713) (← links)
- Detecting treatment differences in group sequential longitudinal studies with covariate adjustment (Q4628379) (← links)
- Treatment Comparisons Based on Two‐Dimensional Safety and Efficacy Alternatives in Oncology Trials (Q4666639) (← links)
- Sequential tests of multiple hypotheses controlling false discovery and nondiscovery rates (Q5113795) (← links)
- (Q5158694) (← links)
- On group sequential tests for data in unequally sized groups and with unknown variance (Q5939504) (← links)
- Improving precision and power in randomized trials for COVID‐19 treatments using covariate adjustment, for binary, ordinal, and time‐to‐event outcomes (Q6055509) (← links)
- Adaptive enrichment designs with a continuous biomarker (Q6055888) (← links)
- Sequential trials in the context of competing risks: concepts and case study, with R and SAS code (Q6625156) (← links)
- Adaptive multiarm multistage clinical trials (Q6627520) (← links)
- Group sequential designs for clinical trials with bivariate endpoints (Q6629838) (← links)
- Adjusting for treatment selection in phase II/III clinical trials with time to event data (Q6629918) (← links)
- Group sequential two-stage preference designs (Q6630272) (← links)
- Group sequential designs for clinical trials when the maximum sample size is uncertain (Q6656333) (← links)
